Detail akcie Olema Pharma Rg online

Business Summary: Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Olema Pharmaceuticals Inc revenues was not reported. Net loss increased 21% to $116.4M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 22% to $128.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.70 to -$1.36.